Date: 2016-04-27
Type of
information: Presentation of results at a congress
phase:
Announcement: presentation of results at the Association for Research in Vision and Ophthalmology (ARVO) 2016 Annual Meeting.
Company: Thrombogenics (Belgium)
Product: Jetrea® (ocriplasmin)
Action
mechanism:
- protein. Ocriplasmin is a truncated form of the human serine protease plasmin that retains its enzymatic properties. This small molecule has been designed specifically for use in the eye. It is believed to primarily target the fibronectin, laminin, and type IV collagen fibers that adhere the vitreous to the retina.By dissolving these proteins, ocriplasmin releases the traction, and helps to complete the detachment of the vitreous from the macula.It works by separating the vitreous humour from the macula, and helping to close the macular hole if one is present which may decrease the symptoms caused by VMT. Ocriplasmin is administered through a one-time, single intravitreal injection.
- Ocriplasmin is currently approved in 54 countries, including in the US.
Disease:
Therapeutic
area: Ophtalmological diseases
Country:
Trial
details:
Latest
news:
- • On April 27, 2016, ThromboGenics announced that the company will be presenting a number of scientific posters and presentations at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2016 Annual Meeting. The Meeting is being held from May 1st – 5th, 2016 in Seattle, US. There will be 15 ocriplasmin-related communications delivered at ARVO. Data presented cover a wide range of presentations, abstracts and posters with preclinical research findings, real-world clinical data, and further characterization of results from different studies, including OASIS, ORBIT, and OVIID-I conducted in the US and Europe.
Among other presentations, ThromboGenics scientists or medical associates will be delivering poster presentations on the following topics:
• Ocriplasmin in a porcine model for PVD induction: to further characterize the activity profile of ocriplasmin at the vitreo-retinal interface.
• Preclinical insights into ocriplasmin safety and mechanism of action: to further confirm safety and mechanism of action of ocriplasmin in its interaction with vitreo-retinal tissues.
• Evaluation of full-field electroretinogram (ERG) changes after ocriplasmin injection in a substudy of symptomatic vitreomacular adhesion subjects from the OASIS trial: to evaluate the relationship of ERG changes with anatomic and visual outcomes for up to 24 months after a single injection of ocriplasmin 0.125 mg.
• Repeated injections of ocriplasmin in the Göttingen mini-pig: to determine safety of up to six consecutive injections of ocriplasmin at 4-week intervals.
Is
general: Yes
